In asynchronous HeLa cells, CD 437 treatment resulted in caspase-3 cleavage, assessed by immunoblotting. In primary cortical neurons undergoing OGD/ROG, increasing concentrations of AHPN produced statistically significant increases in viability and decreases in cell death compared with OGD/ROG without AHPN, as measured by FACS analysis. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Caspase cleavage in asynchronous HeLa cells
Cell-based study · asynchronous HeLa cells [1]
Asynchronous HeLa cells were treated with CD 437 at 5 μM for 8 hours. Immunoblotting showed cleavage of caspase-3.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- 8 hours
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: route.
Methods and source locations
Compound reported in the paper: CD 437
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Results > POLA1 mutations cause CD437 resistance > CD437 toxicity is S-phase dependent (S63); Figure 3 legend (S186, S187)
immunoblotting for caspase-3: immunoblotting for caspase-3; comparator: DMSO — Results > POLA1 mutations cause CD437 resistance > CD437 toxicity is S-phase dependent (S63); Figure 3 legend (S187)
Neuronal viability during OGD/ROG
Cell-based study · primary cortical neurons [2]
Primary cortical neurons received AHPN during OGD/ROG. Compared with OGD/ROG without AHPN, increasing AHPN concentrations produced statistically significant increases in viability and decreases in cell death measured by FACS analysis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 µM
- Exposure duration
- 5 h OGD followed by 16 h ROG
- Method
- during OGD/ROG
- Vehicle
- 0.1% DMSO
- Co-treatment
- Other interventions in this design: OGD/ROG. Compound effect isolated by the comparison: compared with OGD/ROG without AHPN.
Methods and source locations
Compound reported in the paper: CD 437; Compound label in the paper: AHPN
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and methods > OGD and the assessment of cell death (S39); Results > qHTS identified active compounds are capable of inducing protection against oxygen/glucose deprivation (OGD)/restoration of oxygen/glucose (ROG) (S92, S93); Figure 5. legend (S137, S141, S142, S144)
cell death after OGD/ROG as measured by FACS analysis: cell death after OGD/ROG as measured by FACS analysis; comparator: OGD/ROG without AHPN — Figure 5. legend (S141)